These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma. Nargund AM; Pham CG; Dong Y; Wang PI; Osmangeyoglu HU; Xie Y; Aras O; Han S; Oyama T; Takeda S; Ray CE; Dong Z; Berge M; Hakimi AA; Monette S; Lekaye CL; Koutcher JA; Leslie CS; Creighton CJ; Weinhold N; Lee W; Tickoo SK; Wang Z; Cheng EH; Hsieh JJ Cell Rep; 2017 Mar; 18(12):2893-2906. PubMed ID: 28329682 [TBL] [Abstract][Full Text] [Related]
23. Development of a novel interferon-α2b gene construct with a repetitive hypoxia-inducible factor binding site and its suppressive effects on human renal cell carcinoma cell lines in vitro. Fukui N; Kageyama Y; Higashi Y; Kihara K; Kizaka-Kondoh S; Hiraoka M; Shinojima T; Suzuki K; Oya M Int J Clin Oncol; 2014; 19(3):497-504. PubMed ID: 23739923 [TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus. Lin F; Shi J; Liu H; Zhang J; Zhang PL; Wang HL; Yang XJ; Schuerch C Am J Clin Pathol; 2008 Apr; 129(4):592-605. PubMed ID: 18343787 [TBL] [Abstract][Full Text] [Related]
25. Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development. Kuehn EW; Walz G; Benzing T Cancer Res; 2007 May; 67(10):4537-40. PubMed ID: 17510376 [TBL] [Abstract][Full Text] [Related]
26. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma. Gong K; Zhang N; Zhang K; Na Y Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786 [TBL] [Abstract][Full Text] [Related]
27. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma. Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846 [TBL] [Abstract][Full Text] [Related]
28. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Turcotte S; Chan DA; Sutphin PD; Hay MP; Denny WA; Giaccia AJ Cancer Cell; 2008 Jul; 14(1):90-102. PubMed ID: 18598947 [TBL] [Abstract][Full Text] [Related]
29. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362 [TBL] [Abstract][Full Text] [Related]
30. Prognostic and predictive biomarkers in renal cell carcinoma. Vickers MM; Heng DY Target Oncol; 2010 Jun; 5(2):85-94. PubMed ID: 20582732 [TBL] [Abstract][Full Text] [Related]
31. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition. Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960 [TBL] [Abstract][Full Text] [Related]
32. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178 [TBL] [Abstract][Full Text] [Related]
33. [Prognostic factors in renal cell carcinoma]. Wen JJ; Zhou XJ Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):850-3. PubMed ID: 24507112 [No Abstract] [Full Text] [Related]
34. The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells. Razorenova OV; Castellini L; Colavitti R; Edgington LE; Nicolau M; Huang X; Bedogni B; Mills EM; Bogyo M; Giaccia AJ Mol Cell Biol; 2014 Feb; 34(4):739-51. PubMed ID: 24344197 [TBL] [Abstract][Full Text] [Related]
35. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism. Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500 [TBL] [Abstract][Full Text] [Related]
36. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Carroll VA; Ashcroft M Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202 [TBL] [Abstract][Full Text] [Related]
37. miR-30c-2-3p and miR-30a-3p: new pieces of the jigsaw puzzle in HIF2α regulation. Moch H; Lukamowicz-Rajska M Cancer Discov; 2014 Jan; 4(1):22-4. PubMed ID: 24402943 [TBL] [Abstract][Full Text] [Related]
38. Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor. Liu W; Xin H; Eckert DT; Brown JA; Gnarra JR Oncogene; 2011 Jan; 30(1):21-31. PubMed ID: 20802534 [TBL] [Abstract][Full Text] [Related]